CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 pr with inflammatory bowel disease
CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 pr with inflammatory bowel disease
Background: thalidomide, one of whose activities is to inhibit Tumour Necrosis Factor (TNF)-? production, has been reported to be an effective treatment for refractory inflammatory bowel disease (IBD). TNF-? driven production of matrix metalloproteinase (MMP)-3 by gut lamina propria mononuclear cells (LPMCs) is a major pathway of tissue injury in IBD; however the effect of thalidomide and newer more potent immunomodulatory derivatives on this pathway has not been studied.
Aim: to investigate the effect of thalidomide, CC-4047 (pomalidomide), CC-5013 (lenalidomide), and CC-10004 (apremilast) on gut LPMC TNF? and MMP-3 production in patients with IBD.
Methods: gut LPMCs and myofibroblasts were isolated from patients with IBD, and cultured with thalidomide, CC-4047, CC-5013, and CC-10004. MMP-3 and TIMP-1 levels were determined by western blotting and real-time PCR, and TNF-? levels by ELISA.
Results: CC-10004 significantly reduced both TNF-? production and MMP-3 production by cultured LPMCs. Thalidomide and CC-4047 and CC-5013 had no significant effect on the production of TNF-? or MMP-3 by LPMCs.
Conclusion: these results provides a mechanistic rationale for both the failure of lenalidomide (CC-5013) in a recent randomised controlled trial in Crohn's disease, and for the evaluation of CC-10004 as a novel oral therapy in the treatment of CD and UC
175-182
Gordon, J.N.
84de0d58-4db8-4de2-a74e-dc025437e0ce
Prothero, J.D.
87babf58-ecdb-4cd0-8e72-a28e7e5ecde0
Thornton, C.A.
898d425c-5242-458e-8862-852109ee0a64
Pickard, K.M.
e5188669-dff1-49c7-9c6f-8122b0c74bd9
Di Sabatino, A.
7e2802bd-ff3d-4578-862d-1d9c524b78a4
Goggin, P.M.
7cf53c28-7b1c-4737-b500-5746f71e0254
Pender, S.L.
62528b03-ec42-41bb-80fe-48454c2c5242
Macdonald, T.T.
171334aa-638a-42b0-99f6-e860e2f0ca45
September 2009
Gordon, J.N.
84de0d58-4db8-4de2-a74e-dc025437e0ce
Prothero, J.D.
87babf58-ecdb-4cd0-8e72-a28e7e5ecde0
Thornton, C.A.
898d425c-5242-458e-8862-852109ee0a64
Pickard, K.M.
e5188669-dff1-49c7-9c6f-8122b0c74bd9
Di Sabatino, A.
7e2802bd-ff3d-4578-862d-1d9c524b78a4
Goggin, P.M.
7cf53c28-7b1c-4737-b500-5746f71e0254
Pender, S.L.
62528b03-ec42-41bb-80fe-48454c2c5242
Macdonald, T.T.
171334aa-638a-42b0-99f6-e860e2f0ca45
Gordon, J.N., Prothero, J.D., Thornton, C.A., Pickard, K.M., Di Sabatino, A., Goggin, P.M., Pender, S.L. and Macdonald, T.T.
(2009)
CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 pr with inflammatory bowel disease.
Journal of Crohn's and Colitis, 3 (3), .
(doi:10.1016/j.crohns.2009.03.001).
Abstract
Background: thalidomide, one of whose activities is to inhibit Tumour Necrosis Factor (TNF)-? production, has been reported to be an effective treatment for refractory inflammatory bowel disease (IBD). TNF-? driven production of matrix metalloproteinase (MMP)-3 by gut lamina propria mononuclear cells (LPMCs) is a major pathway of tissue injury in IBD; however the effect of thalidomide and newer more potent immunomodulatory derivatives on this pathway has not been studied.
Aim: to investigate the effect of thalidomide, CC-4047 (pomalidomide), CC-5013 (lenalidomide), and CC-10004 (apremilast) on gut LPMC TNF? and MMP-3 production in patients with IBD.
Methods: gut LPMCs and myofibroblasts were isolated from patients with IBD, and cultured with thalidomide, CC-4047, CC-5013, and CC-10004. MMP-3 and TIMP-1 levels were determined by western blotting and real-time PCR, and TNF-? levels by ELISA.
Results: CC-10004 significantly reduced both TNF-? production and MMP-3 production by cultured LPMCs. Thalidomide and CC-4047 and CC-5013 had no significant effect on the production of TNF-? or MMP-3 by LPMCs.
Conclusion: these results provides a mechanistic rationale for both the failure of lenalidomide (CC-5013) in a recent randomised controlled trial in Crohn's disease, and for the evaluation of CC-10004 as a novel oral therapy in the treatment of CD and UC
This record has no associated files available for download.
More information
Published date: September 2009
Identifiers
Local EPrints ID: 179697
URI: http://eprints.soton.ac.uk/id/eprint/179697
ISSN: 1873-9946
PURE UUID: b7cc5d91-8e84-456e-a6d6-d06a37af7755
Catalogue record
Date deposited: 04 Apr 2011 10:29
Last modified: 15 Mar 2024 03:08
Export record
Altmetrics
Contributors
Author:
J.N. Gordon
Author:
J.D. Prothero
Author:
C.A. Thornton
Author:
K.M. Pickard
Author:
A. Di Sabatino
Author:
P.M. Goggin
Author:
T.T. Macdonald
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics